Cargando…
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite
AIMS: Quizartinib is an oral, highly potent and selective next‐generation FMS‐like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3‐internal tandem duplication‐mutated acute myeloid leukaemia. This drug–drug interaction study assessed the pharmacokinetics (PK) of quizarti...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710528/ https://www.ncbi.nlm.nih.gov/pubmed/31173645 http://dx.doi.org/10.1111/bcp.14022 |